The biotech’s licensing pact with Pfizer, revealed last week, will leverage its adjuvant vaccine platform in the development ...

Over the past five years, Novavax ( NVAX 6.01%), a vaccine maker, lost more than 90% of its market value. Though it succeeded ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive ...

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Novavax Inc (NASDAQ:NVAX) shares are trading higher. Reports show a rise in respiratory illnesses across the United States.

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...